Euler A R
J Pediatr. 1980 Feb;96(2):321-4. doi: 10.1016/s0022-3476(80)80839-0.
A double-blind crossover study utilizing bethanechol was performed among 45 pediatric-aged patients with gastroesophageal reflux. Thirty young children (age = less than 1 year) were studied. These infants did significantly better while taking bethanecol than when they were receiving placebo. Fifteen children (age greater than 1 year) were also studied. These patients also had significant clinical improvement while on the drug when compared to the period when they were receiving placebo. Esophageal pH probe testing after the oral administration of bethanecol showed a significant decrease in frequency and duration of episodes of gastroesophageal reflux. This improvement may be secondary to the increases in lower esophageal sphincter pressure and persistaltic activity seen during esophageal manometrics. Bethanechol should be considered for pediatric-aged patients who are not benefited by conventional medical therapeutic regimens.
一项针对45名患有胃食管反流的儿科患者开展了使用氨甲酰甲胆碱的双盲交叉研究。研究了30名幼儿（年龄小于1岁）。这些婴儿服用氨甲酰甲胆碱时的情况明显比接受安慰剂时要好。还研究了15名儿童（年龄大于1岁）。与接受安慰剂期间相比，这些患者在服用药物期间临床症状也有显著改善。口服氨甲酰甲胆碱后的食管pH探头测试显示，胃食管反流发作的频率和持续时间显著降低。这种改善可能是由于食管测压时观察到的食管下括约肌压力和蠕动活动增加所致。对于未从传统药物治疗方案中获益的儿科患者，应考虑使用氨甲酰甲胆碱。
